O
FPRX

OppenheimerFunds’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

OppenheimerFunds’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-125,042
Closed -$4.52M – 1910
2017
Q1 		$4.52M Sell
125,042
-380,798
-75% -$16.8M 0.01% 849
2016
Q4 		$25.3M Buy
505,840
+111,990
+28% +$5.88M 0.03% 502
2016
Q3 		$20.7M Buy
393,850
+2,210
+0.6% +$106K 0.03% 556
2016
Q2 		$16.2M Buy
+391,640
New +$17M 0.02% 617

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

OppenheimerFunds's FPRX Position: Q2 2017 in Review

OppenheimerFunds sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2017, closing a stake of 125,042 shares — an estimated $4.52M sold.

OppenheimerFunds first reported a position in FPRX in Q2 2016 and held it in 4 quarters. The position peaked at $25.3M in Q4 2016. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2017.

  • OppenheimerFunds reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • OppenheimerFunds sold 125,042 Five Prime Therapeutics, Inc. shares in Q2 2017, an estimated $4.52M.
  • OppenheimerFunds first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 4 quarters.
  • OppenheimerFunds's Five Prime Therapeutics, Inc. position peaked at $25.3M in Q4 2016.
  • 123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2017.

Based on OppenheimerFunds's 13F filing for Q2 2017, filed 14 Aug 2017.